Deployment of In-Pharmacy Digital Health Kiosks for Chronic Disease Screening

Abstract

Chronic non-communicable diseases (NCDs) such as hypertension, diabetes, dyslipidemia, and chronic obstructive pulmonary disease (COPD) account for a high and rising share of morbidity and mortality worldwide. Screening coverage remains uneven because traditional models rely on opportunistic testing during clinic visits, are constrained by staff availability, and are often inconvenient for working-age adults. Community pharmacies—high-footfall, extended-hours, neighborhood access points—are well placed to add screening capacity. This manuscript presents a comprehensive, practice-oriented framework for deploying digital health kiosks inside pharmacies to expand early detection of chronic disease risk. We synthesize evidence on pharmacy-based screening, describe a modular kiosk architecture (sensors, software, interoperability, privacy-by-design), and outline an implementation and evaluation methodology aligned with RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance).

To illustrate expected performance, we include results from a notional six-month pilot scenario constructed for demonstration: across 30 pharmacies, 15,240 adults completed kiosk screening; 62% were first-time screeners; 14.1% screened positive for probable hypertension, 7.3% for diabetes (HbA1c ≥6.5% or fasting capillary glucose thresholds), and 22.4% for dyslipidemia risk based on non-fasting lipid panels or total-cholesterol surrogates. Of those with positive screens, 71% completed confirmatory testing within 30 days when supported by automated referral and pharmacist follow-up. Mean screening time was 6.8 minutes, with a median queue time of 2.3 minutes. Estimated program cost was $8.70 per person screened and $64–$128 per new case confirmed, depending on condition. User satisfaction averaged 4.5/5, and pharmacies reported minimal workflow disruption after week three of rollout.

We conclude that in-pharmacy digital kiosks can materially increase screening reach and timely detection when integrated with pharmacist counseling, consented data-sharing (HL7 FHIR), and structured referral pathways. Key enablers include multilingual UX, validated sensors, role-based access controls, and simple reimbursement models. Limitations include potential selection bias, false positives from single-visit measurements, and the need for robust device maintenance. Future work should include stepped-wedge trials with longer follow-up, health economic evaluations, and equity-focused design to close gaps for underserved groups.